PharmStars Ventures Fund 1 LP

The absence of prior EDGAR filings from this manager confirms this is a first raise, meaning the fund's 8% close rate ($4M of $50M) reflects early-stage relationship capital rather than institutional momentum or a follow-on dynamic; LPs should establish whether these initial backers are institutional anchors or seed checks from operational networks.

A June 2026 filing for a life sciences venture fund aligns with sustained biopharma investment cycles and potential LP rebalancing into specialty VC after public market volatility, though the slow pace (8% closure) suggests the fund is either in extended quiet fundraising or competing in a saturated pharma-focused fund cohort.

Verify whether a key-man clause exists and which GP triggers it—with only two named principals and no disclosed operating history, concentration risk is material; also confirm whether the 06b exemption covers all $50M or signals a planned institutional close that would require Regulation D compliance.